Literature DB >> 18484680

Comparison of mania patients suitable for treatment trials versus clinical treatment.

Alessandra Talamo1, Ross J Baldessarini, Franca Centorrino.   

Abstract

It remains uncertain whether bipolar disorder (BPD) patients in randomized-controlled trials (RCTs) are sufficiently representative of clinically encountered patients as to guide clinical-therapeutic practice. We complied inclusion/exclusion criteria by frequency from reports of 21 RCTs for mania, and applied them in a pilot study of patients hospitalized for DSM-IV BPD manic/mixed states to compare characteristics and clinical responses of patients who did versus did not meet exclusion criteria. From 27 initially identified inclusion/exclusion criteria ranked by citation frequency, we derived six inclusion, and 10 non-redundant-exclusion factors. Of 67 consecutive patients meeting inclusion criteria, 15 (22.4%) potential "research subjects" met all 10 exclusion criteria. The remaining 52 "clinical patients" differed markedly on exclusion criteria, including more psychiatric co-morbidity, substance abuse, involuntary hospitalization, and suicide attempts or violence, but were otherwise similar. In both groups responses to clinically determined inpatient treatments were similar, including improvement in mania ratings. Based on applying reported inclusion/exclusion criteria for RCTs to a pilot sample of hospitalized-manic patients, those likely to be included in modern RCTs were similar to patients who would be excluded, most notably in short-term antimanic-treatment responses. The findings encourage further comparisons of subjects included/excluded from RCTs to test potential clinical generalizability of research findings. The pilot study is limited in numbers and exposure times with which to test for the minor differences between "research subjects" and "clinical patients." (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2008        PMID: 18484680      PMCID: PMC2643874          DOI: 10.1002/hup.952

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  53 in total

1.  Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study.

Authors:  D A Regier; M E Farmer; D S Rae; B Z Locke; S J Keith; L L Judd; F K Goodwin
Journal:  JAMA       Date:  1990-11-21       Impact factor: 56.272

2.  Analysis of randomized and nonrandomized patients in clinical trials using the comprehensive cohort follow-up study design.

Authors:  M Olschewski; M Schumacher; K B Davis
Journal:  Control Clin Trials       Date:  1992-06

3.  Users' guides to the medical literature: XIV. How to decide on the applicability of clinical trial results to your patient. Evidence-Based Medicine Working Group.

Authors:  A L Dans; L F Dans; G H Guyatt; S Richardson
Journal:  JAMA       Date:  1998-02-18       Impact factor: 56.272

4.  Generalisability of results from randomised drug trials. A trial on antimanic treatment.

Authors:  R W Licht; G Gouliaev; P Vestergaard; M Frydenberg
Journal:  Br J Psychiatry       Date:  1997-03       Impact factor: 9.319

Review 5.  Lack of insight in psychotic and affective disorders: a review of empirical studies.

Authors:  S N Ghaemi; H G Pope
Journal:  Harv Rev Psychiatry       Date:  1994 May-Jun       Impact factor: 3.732

6.  Maintenance clinical trials in bipolar disorder: design implications of the divalproex-lithium-placebo study.

Authors:  C L Bowden; A C Swann; J R Calabrese; S L McElroy; D Morris; F Petty; R M Hirschfeld; L Gyulai
Journal:  Psychopharmacol Bull       Date:  1997

7.  A new depression scale designed to be sensitive to change.

Authors:  S A Montgomery; M Asberg
Journal:  Br J Psychiatry       Date:  1979-04       Impact factor: 9.319

8.  Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BD.

Authors:  Naomi M Simon; Michael W Otto; Roger D Weiss; Mark S Bauer; Sachiko Miyahara; Stephen R Wisniewski; Michael E Thase; Jane Kogan; Ellen Frank; Andrew A Nierenberg; Joseph R Calabrese; Gary S Sachs; Mark H Pollack
Journal:  J Clin Psychopharmacol       Date:  2004-10       Impact factor: 3.153

Review 9.  Illness characteristics of patients in clinical drug studies of mania.

Authors:  C L Bowden; J R Calabrese; B A Wallin; A C Swann; S L McElroy; S C Risch; M A Hirschfeld
Journal:  Psychopharmacol Bull       Date:  1995

10.  Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial.

Authors:  Robert M A Hirschfeld; Paul E Keck; Michelle Kramer; Keith Karcher; Carla Canuso; Marielle Eerdekens; Fred Grossman
Journal:  Am J Psychiatry       Date:  2004-06       Impact factor: 18.112

View more
  3 in total

1.  From Randomized Controlled Trials of Antidepressant Drugs to the Meta-Analytic Synthesis of Evidence: Methodological Aspects Lead to Discrepant Findings.

Authors:  Konstantinos N Fountoulakis; Roger S McIntyre; André F Carvalho
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

2.  A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results.

Authors:  Tessa Kennedy-Martin; Sarah Curtis; Douglas Faries; Susan Robinson; Joseph Johnston
Journal:  Trials       Date:  2015-11-03       Impact factor: 2.279

Review 3.  Exclusion criteria and generalizability in bipolar disorder treatment trials.

Authors:  Jessie J Wong; Nev Jones; Christine Timko; Keith Humphreys
Journal:  Contemp Clin Trials Commun       Date:  2018-01-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.